Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Fishman

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
The New England Journal of Medicine|March 31, 2016
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice OffendersJoshua D Lee, Peter D Friedmann, Timothy W Kinlock, et al.
Substance Abuse|June 3, 2022
Opioid use disorder Cascade of care framework design: A roadmapArthur Robin Williams, Kimberly A Johnson, Cindy Parks Thomas, et al.
Lancet (London, England)|November 19, 2017
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trialJoshua D Lee, Edward V Nunes, Patricia Novo, et al.
The Oncologist|February 15, 2021
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse ReactionsCharles L Bennett, Sumimasa Nagai, Andrew C Bennett, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|August 30, 2011
Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disordersPaula D Riggs, Theresa Winhusen, Robert D Davies, et al.
Medicina (Kaunas, Lithuania)|April 23, 2022
Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among YouthMichael Krausz, Jean N Westenberg, Vivian Tsang, et al.
Eclinicalmedicine|February 8, 2021
Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)Charles L Bennett, Shamia Hoque, Nancy Olivieri, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
The New England Journal of Medicine|March 31, 2016
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice OffendersJoshua D Lee, Peter D Friedmann, Timothy W Kinlock, et al.
Substance Abuse|June 3, 2022
Opioid use disorder Cascade of care framework design: A roadmapArthur Robin Williams, Kimberly A Johnson, Cindy Parks Thomas, et al.
Lancet (London, England)|November 19, 2017
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trialJoshua D Lee, Edward V Nunes, Patricia Novo, et al.
The Oncologist|February 15, 2021
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse ReactionsCharles L Bennett, Sumimasa Nagai, Andrew C Bennett, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|August 30, 2011
Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disordersPaula D Riggs, Theresa Winhusen, Robert D Davies, et al.
Medicina (Kaunas, Lithuania)|April 23, 2022
Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among YouthMichael Krausz, Jean N Westenberg, Vivian Tsang, et al.
Eclinicalmedicine|February 8, 2021
Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)Charles L Bennett, Shamia Hoque, Nancy Olivieri, et al.
Pageof 8